Antiviral Effect of 4 Regimens of PEGASYS Plus Copegus in Patients With Genotype 1 Chronic Hepatitis C Non-Responder to Previous Peginterferon Alfa-2a Plus Ribavirin Therapy

Trial Profile

Antiviral Effect of 4 Regimens of PEGASYS Plus Copegus in Patients With Genotype 1 Chronic Hepatitis C Non-Responder to Previous Peginterferon Alfa-2a Plus Ribavirin Therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2014

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms SYREN
  • Sponsors Roche
  • Most Recent Events

    • 26 May 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 26 Apr 2009 Interim results presented at EASL 2009.
    • 17 Sep 2008 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top